EUVIMEDEUVIMED entdecken
Vergleichsstudie

Cardiovascular outcomes among giant cell myocarditis compared with cardiac sarcoidosis: A propensity score-matched analysis

Vikash Jaiswal, Muhammad Hanif, Yusra Mashkoor, Aanchal Sawhney, Tushar Kumar, Juveriya Yasmeen, F N U Sundas, Jishanth Mattumpuram, Adrija Hajra, Carl J Lavie, Dhrubajyoti Bandyopadhyay

Progress in Cardiovascular Diseases · 2025

DOI: 10.1016/j.pcad.2024.11.002 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Progress in Cardiovascular Diseases, 2025. Verfasst von Vikash Jaiswal und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Research, Larkin Community Hospital, South Miami, FL, USA. Hauptthemen laut MEDLINE: Sarcoidosis, Myocarditis, Cardiomyopathies, Giant Cells. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Giant cell myocarditis (GCM) and cardiac sarcoidosis (CS) are rare inflammatory diseases of the myocardium with poor prognosis. Cardiovascular disease outcomes among both diseases have not been well studied with limited literature. OBJECTIVE: This study aims to investigate the cardiovascular outcomes among patients with GCM and CS. METHOD: We queried the TriNeTX Global Collaborative Network for adult patients with giant cell myocarditis and cardiac sarcoidosis between January 2000 to May 2023 and created two groups: one with giant cell myocarditis and second with cardiac sarcoidosis. Both the groups were followed for 6 months and 12 months. RESULT: After propensity score matched analysis (PSM), among the 4804 patients (2402 patients in each group), the mean age of patients was 57.1 and 57.6 years in GCM and CS groups, respectively. PSM analysis showed that primary outcome i.e., all-cause mortality was significantly higher in GCM group both after 6 months [relative risk (RR) 2.33, 95 % confidence interval (CI): 1.64-3.30, p < 0.01] and 1 year follow up [RR, 1.54 (95 % CI: 1.20-1.98), p < 0.01] as compared with CS group. However, secondary outcomes i.e., heart failure (HF) at 6 month (RR 0.66, 95 % CI: 0.52-0.85, p < 0.01), and at 1 year (RR 0.60, 95 % CI: 0.49-0.73, p < 0.01), ventricular tachycardia (VT) at 6 months (RR 0.34, 95 % CI: 0.25-0.46, p < 0.01), and at 1 year (RR 0.32, 95 % CI: 0.25-0.41, p < 0.01), atrioventricular (AV) node block at 6 month (RR 0.45, 95 % CI: 0.33-0.61, p < 0.01), and at 1 year (RR 0.43, 95 % CI: 0.34-0.55, p < 0.01), and atrial flutter and fibrillation (AF) at 6 months (RR 0.67, 95 % CI: 0.48-0.94, p = 0.02), and at 1 year (RR 0.59, 95 % CI: 0.45-0.76, p < 0.01) were found significantly lower in GCM group as compared to CS group. On the other hand, heart transplant incidence was comparable between both the groups. CONCLUSION: These findings suggest that GCM patients have high risk of mortality and lower risk of HF, VT, AV node block, and AF when compared with CS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SarcoidosisMyocarditisCardiomyopathiesGiant CellsHumansFemaleMiddle AgedMalePropensity ScoreTime FactorsRisk AssessmentRetrospective StudiesRisk FactorsPrognosisAdultAgedCause of DeathDatabases, Factual

Stichwörter der Autor:innen

ArrhythmiasCardiac sarcoidosisCardiovascular outcomesGiant cell myocarditisHeart failure

Autor:innen und Institutionen

  • Department of Cardiovascular Research, Larkin Community Hospital, South Miami, FL, USA.
  • Department of Internal Medicine, SUNY Upstate Medical University, Syracuse, NY, USA.
  • Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan.
  • Department of Internal Medicine, Crozer Chester Medical Center, Upland, PA, USA.
  • Department of Cardiothoracic and Abdominal Radiology, University of Washington, Seattle, WA, USA.
  • Department of Internal Medicine, Saint Joseph Hospital, Chicago, USA.

Zitieren

APA

Jaiswal, V., Hanif, M., Mashkoor, Y., Sawhney, A., Kumar, T., Yasmeen, J., Sundas, F. N. U., Mattumpuram, J., Hajra, A., Lavie, C. J., & Bandyopadhyay, D. (2025). Cardiovascular outcomes among giant cell myocarditis compared with cardiac sarcoidosis: A propensity score-matched analysis. Progress in Cardiovascular Diseases. https://doi.org/10.1016/j.pcad.2024.11.002

Vancouver

Jaiswal V, Hanif M, Mashkoor Y, Sawhney A, Kumar T, Yasmeen J, et al. Cardiovascular outcomes among giant cell myocarditis compared with cardiac sarcoidosis: A propensity score-matched analysis. Progress in Cardiovascular Diseases. 2025. doi:10.1016/j.pcad.2024.11.002

BibTeX
@article{Jaiswal2025,
  author = {Jaiswal, Vikash and Hanif, Muhammad and Mashkoor, Yusra and Sawhney, Aanchal and Kumar, Tushar and Yasmeen, Juveriya and Sundas, F N U and Mattumpuram, Jishanth and Hajra, Adrija and Lavie, Carl J and Bandyopadhyay, Dhrubajyoti},
  title = {Cardiovascular outcomes among giant cell myocarditis compared with cardiac sarcoidosis: A propensity score-matched analysis},
  journal = {Progress in Cardiovascular Diseases},
  year = {2025},
  doi = {10.1016/j.pcad.2024.11.002}
}
Kostenlos starten →